Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.065
−$0.005 · -0.47%
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
Regular session
$1.065
−$0.005 · -0.47%
Regular session · ET · Market data may be delayed.
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
Day range
Current $1.065
52-week range
Current $1.065
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
53
Mixed
Risk
69
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
Day range
Current $1.065
52-week range
Current $1.065
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 5.06M USD | 12.54M USD | 15.17M USD | 12.39M USD | 8.79M USD |
| Gross profit | −5.06M USD | −12.54M USD | −15.17M USD | −12.39M USD | −8.79M USD |
| Research and development | 5.06M USD | 12.54M USD | 15.17M USD | 12.39M USD | 8.79M USD |
| Selling, general, and administrative | 3.96M USD | 5.34M USD | 5.99M USD | 5.75M USD | 5.43M USD |
| Operating expenses | 3.96M USD | 5.34M USD | 3.39M USD | 26.44M USD | 5.43M USD |
| Interest income | 134K USD | 537K USD | 640K USD | 2 USD | 4 USD |
| Interest expense | — | — | — | 2K USD | 4K USD |
| Depreciation and amortization | 376K USD | 126K USD | 189K USD | 388K USD | 190K USD |
| Operating income | −9.02M USD | −17.88M USD | −18.56M USD | −38.83M USD | −14.22M USD |
| Net income | −8.83M USD | −17.5M USD | −17.98M USD | −38.84M USD | −14.19M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 11, 2022 | 1:12 | — | — |
Stock split | Jan 24, 2018 | 1:30 | — | — |
Stock split | Mar 15, 2011 | 10:1 | — | — |
Effective Oct 11, 2022
1:12
Effective Jan 24, 2018
1:30
Effective Mar 15, 2011
10:1
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
